108 related articles for article (PubMed ID: 10705778)
1. [Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia].
Parola D; Dell'Orso D; Terzano C
Recenti Prog Med; 2000 Jan; 91(1):12-5. PubMed ID: 10705778
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
3. Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections.
Rocha RT; Awad CE; Ali A; Matyas R; Vital AC; Silva CO; Dainesi SM; Salazar MS; Nakatani J
Int J Clin Pract; 1999 Sep; 53(6):433-6. PubMed ID: 10622070
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
Stein GE; Mantz SL
Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
Aurangzeb B; Hameed A
J Coll Physicians Surg Pak; 2003 Dec; 13(12):704-7. PubMed ID: 15569557
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
[TBL] [Abstract][Full Text] [Related]
7. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
9. Clarithromycin in the management of community-acquired pneumonia.
McCarty JM
Clin Ther; 2000 Mar; 22(3):281-94; discussion 265. PubMed ID: 10963284
[TBL] [Abstract][Full Text] [Related]
10. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
11. [Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy].
Fernández P; San Martín L
Rev Med Chil; 2000 Mar; 128(3):267-72. PubMed ID: 10962867
[TBL] [Abstract][Full Text] [Related]
12. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.
Micek ST; Kollef KE; Reichley RM; Roubinian N; Kollef MH
Antimicrob Agents Chemother; 2007 Oct; 51(10):3568-73. PubMed ID: 17682100
[TBL] [Abstract][Full Text] [Related]
13. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia.
Lee PI; Wu MH; Huang LM; Chen JM; Lee CY
J Microbiol Immunol Infect; 2008 Feb; 41(1):54-61. PubMed ID: 18327427
[TBL] [Abstract][Full Text] [Related]
14. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.
Ramirez JA; Srinath L; Ahkee S; Huang A; Raff MJ
Arch Intern Med; 1995 Jun; 155(12):1273-6. PubMed ID: 7778957
[TBL] [Abstract][Full Text] [Related]
15. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
[TBL] [Abstract][Full Text] [Related]
17. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
[TBL] [Abstract][Full Text] [Related]
18. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
20. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
